Crescent Biopharma Statistics
Total Valuation
CBIO has a market cap or net worth of $242.22 million. The enterprise value is $247.09 million.
Important Dates
The next estimated earnings date is Sunday, November 23, 2025, after market close.
| Earnings Date | Nov 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CBIO has 19.55 million shares outstanding.
| Current Share Class | 13.89M |
| Shares Outstanding | 19.55M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +2,273.50% |
| Owned by Insiders (%) | 7.89% |
| Owned by Institutions (%) | 42.15% |
| Float | 6.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.62
| Current Ratio | 3.62 |
| Quick Ratio | 3.62 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.18 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -264.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$11.91M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Dividends & Yields
CBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -29.25% |
| FCF Yield | n/a |
Dividend Details Analyst Forecast
The average price target for CBIO is $25.60, which is 106.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.60 |
| Price Target Difference | 106.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |